FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL

Season 3 Episode 26  ·  Aug 03, 2020, 08:04 PM
Headliner
Share
Subscribe

In an interview with OncLive, Dr. Wang discusses the FDA approval of brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Share
Subscribe
Next
Dizon Discusses Elements of Sexual Health in Gynecologic Cancer
Top episodes
DeNunzio Describes the Advantages of Proton Beam Therapy in Oncology
by OncLive® On Air
FDA Approval Insights: Amivantamab and Mobocertinib in EGFR Exon 20 Insertion+ NSCLC
by OncLive® On Air
Milhem Talks Mechanism of Action, Delivery Methodology, and Ongoing Trials With RP1
by OncLive® On Air